Only two drugs inhibiting IL-6 or the IL-6R are currently approved for clinical use; tocilizumab is used in rheumatoid arthritis and systemic sclerosis, whereas siltuximab is approved for treatment of multicentric Castleman’s disease (Table 6). The gene discussed is IL6; the disease is rheumatoid arthritis.